Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours
- 1 November 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (17) , 2272-2278
- https://doi.org/10.1016/s0959-8049(02)00379-9
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2001
- Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic DevelopmentJournal of Clinical Oncology, 1999
- CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agentsTrends in Pharmacological Sciences, 1997
- THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICSAnnual Review of Pharmacology and Toxicology, 1997
- Farnesyltransferase inhibitors and anti-Ras therapyBreast Cancer Research and Treatment, 1996
- Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeuticCell, 1994
- The Ras signal transduction pathwayCancer and Metastasis Reviews, 1994
- FUNCTION AND REGULATION OF RASAnnual Review of Biochemistry, 1993
- Ras C-terminal processing enzymes—New drug targets?Cell, 1991
- Noncompartmental Analysis Based on Statistical Moment TheoryPublished by Taylor & Francis ,1982